REG - Alliance Pharma PLC - AGM Statement <ALAPH.L>
.
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100527:nRSa6282Ma
RNS Number : 6282M
Alliance Pharma PLC
27 May 2010
For immediate release 27 May 2010
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
AGM Statement
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting in London
later
this morning.
Michael Gatenby, the Company's Chairman, will make the following comments:
"I am pleased to report that trading in the first four months of 2010 has been ahead of our expectations and
significantly
ahead of last year. Alliance continues to benefit from the positive sales trends reported at the time of the Company's
preliminary results.
"Turnover in the four month period ended 30 April 2010 was £15.0 million, 88% higher than the same period in 2009. This
four month period includes £2.7 million of sales from the products acquired from Cambridge Laboratories in February 2010
and from Reckitt Benckiser in August 2009.
"Sales of Deltacortril# / enteric coated prednisolone tablets continue to be strong. We remain cautious that the
prednisolone market may become more competitive over time, though this has not happened to date.
"The Cambridge Laboratories acquisition has been successfully integrated into Alliance ahead of schedule. Sales by
Alliance of the Cambridge Laboratories products in the first 10 weeks post-acquisition have been in line with our
expectations.
"We look forward to the remainder of 2010 with confidence."
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney
Corporate Broking: David Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights
to
more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the
treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's
disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are
distributed both to hospitals directly and to pharmaceutical wholesalers, which in turn service both hospital and retail
pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
